Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Pellentesque dignissim sapien semper
$78.00Add to cartCras luctus ultricies ex luctus malesuada. Fusce imperdiet interdum consectetur. Pellentesque dignissim sapien semper consequat sollicitudin. Phasellus iaculis libero ac placerat aliquam. Etiam a velit eu diam consequat vestibulum. Ut a malesuada nulla. Vivamus quis maximus nisi, vel molestie sapien. Nunc pharetra finibus elit sed consectetur.
-
Quick View
Vestibulum ante ipsum primis
$56.00Add to cartCras mollis dolor sed tempor iaculis. Duis ac ante quam. Donec nec justo erat. Nam a augue vel ex venenatis interdum sit amet ac quam. Interdum et malesuada fames ac ante ipsum primis in faucibus. Vestibulum erat lectus, cursus at dui in, fringilla commodo lectus. Quisque eu bibendum quam, eget euismod sem
-
Quick View
Phasellus molestie id mi sit amet
$66.00Add to cartMorbi mattis ipsum sem, in gravida dolor venenatis vestibulum. Aenean laoreet, nisi in bibendum dictum, purus libero accumsan enim, id vehicula enim metus vitae ipsum. Maecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat.
-
Quick View
Curabitur ultricies ante ultricies blandit
$88.00Add to cartCurabitur ultricies ante ultricies blandit placerat. Phasellus fermentum, ligula sed vestibulum blandit, mi odio laoreet sem, a venenatis tellus felis eu justo. Nullam ut felis et mauris iaculis malesuada. Donec non turpis vel lectus accumsan rutrum. Vestibulum finibus nunc libero, vel dapibus mauris porta vitae.
Reviews
There are no reviews yet.